Insider Buying: Surrozen (NASDAQ:SRZN) Major Shareholder Purchases $603,473.36 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 30,884 shares of the stock in a transaction dated Friday, December 5th. The shares were purchased at an average price of $19.54 per share, with a total value of $603,473.36. Following the completion of the transaction, the insider owned 981,890 shares of the company’s stock, valued at approximately $19,186,130.60. This trade represents a 3.25% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The stock was purchased at an average price of $17.35 per share, for a total transaction of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III bought 315,457 shares of Surrozen stock. The shares were purchased at an average cost of $12.65 per share, for a total transaction of $3,990,531.05.

Surrozen Price Performance

Shares of Surrozen stock opened at $23.95 on Thursday. The stock has a market capitalization of $205.25 million, a price-to-earnings ratio of -1.07 and a beta of 0.62. The business has a 50-day moving average of $14.46 and a 200 day moving average of $11.60. Surrozen, Inc. has a 12 month low of $5.90 and a 12 month high of $24.86.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Friday, November 7th. The company reported ($3.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The business had revenue of $0.98 million for the quarter. Equities research analysts anticipate that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Institutional Investors Weigh In On Surrozen

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Citadel Advisors LLC lifted its position in shares of Surrozen by 32.8% during the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after purchasing an additional 3,424 shares during the last quarter. Geode Capital Management LLC raised its stake in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after buying an additional 5,702 shares in the last quarter. Heights Capital Management Inc. purchased a new stake in Surrozen during the 1st quarter worth about $524,000. Woodline Partners LP purchased a new stake in Surrozen during the 3rd quarter worth about $621,000. Finally, Armistice Capital LLC acquired a new position in shares of Surrozen during the 2nd quarter worth about $536,000. 66.57% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on SRZN shares. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Surrozen to a “sell” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.